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Unstructured summary 19 
 20 
Sarcopenia is a progressive and generalised skeletal muscle disorder involving the 21 
accelerated loss of muscle mass and function that is associated with increased adverse 22 
outcomes including falls, functional decline, frailty and mortality. It occurs commonly as 23 
an age-related process in older people, influenced not only by contemporaneous risk 24 
factors but also by genetic and lifestyle factors operating across the life course. It can also 25 
occur in mid-life in association with a range of conditions. In recent years, sarcopenia has 26 
become the focus of intense research aiming to translate increased understanding about 27 
pathophysiology into improved diagnosis and treatment, with particular interest in the 28 
development of biomarkers, nutritional interventions, and drugs to augment the 29 
beneficial effects of resistance exercise. There is also interest in designing effective 30 
preventive strategies across the life course. It is likely that the diagnosis, treatment and 31 
prevention of sarcopenia will soon become part of routine clinical practice.  32 
  33 
 3 
Fast facts / One page summary 34 
 35 
• Sarcopenia is a progressive and generalised skeletal muscle disorder involving the 36 
accelerated loss of muscle mass and function that is associated with increased 37 
adverse outcomes including falls, functional decline, frailty and mortality.  38 
• Dıagnosıs of sarcopenıa relıes on measurıng muscle strength, muscle mass and 39 
physıcal performance, although dıfferent defınıtıons and cut-off poınts have been 40 
proposed. Blood bıomarkers are not yet avaılable ın clınıcal practıce. The 41 
EWGSOP2 defınıtıon has been endorsed by several ınternatıonal socıetıes. 42 
• Case fındıng ın patıents wıth relevant symptoms (falls, weakness, slowness, 43 
functıonal ımpaırments) ıs recommended. The SARC-F questionnaire can be used 44 
for screenıng ın hıgh prevalence settıngs. 45 
• A syndromıc approach ıs recommended to ascertaın the underlyıng causes. 46 
• Dıfferentıal dıagnosıs has to be made wıth malnutrition, caquexıa and fraılty. 47 
• The prevalence of sarcopenıa ıncreases wıth age and ıs hıgher ın some care 48 
settıngs (acute hospıtal admission, nursıng homes). 49 
• Pathophysıology ıs complex and ınvolves many pathways and systems. 50 
• Guıdelınes recommend resıstance exercıse as the cornerstone for treatment of 51 
sarcopenıa. Evıdence on nutrıtıon ınterventıons ıs less consıstent. 52 
• There are no drugs approved for sarcopenıa. 53 
• Muscle strength and physıcal performance can be used to assess the effect of 54 
ınterventıons ın clınıcal practıce. 55 
• The preventıon of sarcopenıa ıs now a major area of research actıvıty, usıng a lıfe 56 
course perspectıve. 57 
• An ICD-10 code for sarcopenia was announced in 2016. It is likely that the 58 
diagnosis, treatment and prevention of sarcopenia will soon become part of 59 
routine clinical practice.   60 
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 61 
Background  62 
Sarcopenia is a term derived from the Greek ‘poverty of flesh’. It was first described in the 63 
1980s as an age-related decline in lean body mass affecting mobility, nutritional status 64 
and independence.1 The definition has since evolved and there have been two recent 65 
milestones. The first was the introduction of muscle function into the concept in six 66 
consensus definitions since 2010.2–7 This new focus on muscle function, usually defined by 67 
muscle strength but also by muscle power or physical performance, occurred because 68 
function was consistently shown to be a more powerful predictor of  clinically relevant 69 
outcomes than muscle mass alone.8–11 The second milestone was recognition of 70 
sarcopenia as an independent condition with an ICD-10 code in 2016.12 Yet most clinicians 71 
remain unaware of the condition and the diagnostic tools needed to identify it.13,14 This 72 
review describes recent progress and debate about a consensus definition, an approach to 73 
diagnosis and case finding, an overview of disease burden and pathophysiology, an outline 74 
of current treatment strategies, and future potential for prevention across the life course. 75 
 76 
Definition 77 
Sarcopenia has recently been defined as a progressive and generalised skeletal muscle 78 
disorder involving the accelerated loss of muscle mass and function that is associated with 79 
increased adverse outcomes including falls, functional decline, frailty and mortality.15 80 
When first coined, the word sarcopenia referred to an age-related loss of muscle mass and 81 
function.1 However for decades it was used to describe muscle wasting (low muscle mass) 82 
alone without reference to function, and this concept is still used in some cancer and 83 
other disease-related sarcopenia research today. Nevertheless there has been some 84 
progress in recent years, and published consensus definitions by a range of expert groups 85 
from around the world now include muscle function in the concept of sarcopenia. Full 86 
agreement on the variables to be included and cut points has yet to be reached (Table 1). 87 
The most widely cited definition at this time is that proposed by the European Working 88 
Group on Sarcopenia in Older People (EWGSOP),3 supported by the Asian Working Group 89 
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on Sarcopenia (AWGS)6 and recently updated as EWGSOP2.15 This is the only definition 90 
currently endorsed by a range of international scientific societies (EuGMS, ESPEN, ESCEO, 91 
IOF, IAGG-ER) for clinical practice and research. 92 
 93 
Table 1. Definitions of sarcopenia 94 
 95 
Definition Muscle 
mass 
Muscle 
strength 
Physical 
performance 
Cut-offs 
defined 
Comment 
EWGSOP (2010)3 • • •   
IWGS (2011)4 •  • •  
SSCWD (2011)5 •  • • Named 
“sarcopenia 
with limited 
mobility” 
AWGS (2014)6 • • • • Same as 
EWGSOP but 
adds cutoffs 
for Asia 
FNIH (2014)7 • •  • Uses 
physical 
performance 
as outcome 
EWGSOP2 
(2019)15 
• • • • Physical 
performance 
used for 
severity 
 96 
In clinical practice, the EWGSOP2 states that a person with low muscle strength and low 97 
muscle mass or quality will be diagnosed with sarcopenia. It may be best understood as 98 
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organ (skeletal muscle) failure or insufficiency.16 As such, it may appear acutely (usually in 99 
the setting of an acute disease or sudden immobility, as during hospital admission) or 100 
have a more protracted (chronic) course. Muscle mass and strength (in parallel with bone 101 
mineral density) peak in young adulthood and, after a plateau, start decreasing gradually, 102 
with a faster decline in strength (figure 1).17,18  The World Health Organization has recently 103 
shifted its paradigm from a disease-centered to a function-centered model, where 104 
intrinsic capacity (defined as a composite of all physical and mental capacities of an 105 
individual) interacts with the environment to determine functional ability. Muscle strength 106 
is included in the construct of intrinsic capacity that may merit lifelong monitoring.19,20 107 
 108 
Clinicians may associate sarcopenia with leanness and not be aware that sarcopenia can 109 
also be present in obesity,  leading to increased disability and mortality.21 Sarcopenic 110 
obesity is usually identified when both low muscle mass and increased adiposity are 111 
present in an individual, but it may remain unnoticed when the focus of care is obesity, 112 
leading to adverse outcomes.22 Sarcopenia and obesity share some underlying 113 
pathophysiological pathways.23 Muscle loss may also increase the risks during weight loss 114 
in obese individuals.24,25 However a consensus definition of sarcopenic obesity to date is 115 
lacking, and how muscle strength should  be used to make a diagnosis in this setting 116 
remains unclear.21,22,26 There is also a relationship between sarcopenia and dysphagia 27 117 
(sarcopenic dysphagia) that merits a specific approach in clinical practice.28 118 
 119 
Case finding 120 
Most cases of sarcopenia go undiagnosed. Nevertheless, at this time, there is no evidence 121 
to support universal screening of sarcopenia as screening tools are not accurate 29–32 and 122 
the effect of such screening on relevant outcomes is far from proved.33 Therefore, a case 123 
finding approach is current recommended practice.15 This involves looking for sarcopenia 124 
when relevant symptoms are reported. These could include falling, weakness, slowness, 125 
self-reported muscle wasting, or difficulties carrying out the activities of daily living.5,15 126 
Case finding is particularly relevant in care settings where a higher prevalence of 127 
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sarcopenia may be expected such as acute hospitalisation, rehabilitation settings, or 128 
nursing homes.34,35 The SARC-F is a commonly recommended case finding instrument with 129 
evidence to support its use.33,36 It can be self-administered and has a low sensitivity but 130 
high specificity, so may be a good way to initiate identifying cases of sarcopenia in clinical 131 
practice (Table 2).31,37 132 
 133 
Table 2. Components of the SARC-F screening test 134 
 135 
This screening instrument has five questions addressing: 136 
• Strength  137 
• Assistance in walking  138 
• Rise from a chair  139 
• Climb stairs  140 
• Falls  141 
 142 
Diagnosis 143 
The diagnosis of sarcopenia using any definition of sarcopenia is relatively straightforward. 144 
It requires measurement of a combination of muscle mass, muscle strength and physical 145 
performance (table 1). All definitions use at least two parameters but different cut points 146 
leading to lack of standardisation and poor application of these definitions in clinical 147 
practice14. The updated European Working Group on Older People (EWGSOP2) has 148 
proposed a stepwise approach (figure 2). It starts with a measure of muscle strength, 149 
usually grip strength which has a well validated protocol.38 If grip strength is below the 150 
reference values for gender (table 3 or those proposed by the definitions listed in table 1), 151 
sarcopenia should be suspected. However, the differential diagnosis is wide and other 152 
potential causes for low muscle strength should be considered, for example hand 153 
osteoarthritis and neurological disorders.  Nevertheless identifying low grip strength in the 154 
first instance is important because it is highly predictive of a range of adverse 155 
outcomes.39–42 156 
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The second step is measuring muscle mass. A number of techniques have been used to 157 
estimate muscle mass, but all have major limitations, including variability in the results, 158 
inconsistent use of cut points, and the weak relationship between muscle mass and 159 
adverse health outcomes.39 Best agreement to date exists for the use of dual energy X-ray 160 
absorptiometry (DXA), which estimates lean mass, whilst bioimpedance absorptiometry 161 
(BIA), computerized tomography (CT) and magnetic resonance imaging (MRI) may have a 162 
role in some settings.43 BIA is useful as a bedside test, but as BIA equations and cut points 163 
are population and device-specific there is a lack of standardisation that limits its 164 
accuracy.44 CT and MRI are mostly used in research and also when needed for the follow-165 
up of another condition, as in cancer patients.45  Ultrasound has been recently been 166 
proposed as a simple alternative to measure muscle mass in clinical practice, but it is not 167 
standardised and does not have validated cut points yet.46,47 Usually, appendicular lean 168 
mass (skeletal muscle in the extremities) is measured, and in most cases adjustment for 169 
height is used to define cut-off values. Unfortunately research focused on identifying cut 170 
points to define sarcopenia has led to a range of different values that are difficult to 171 
reconcile and introduce systematically.48,49 For this reason, the EWGSOP2 definition has 172 
taken a pragmatic approach and opted for simple, easy to remember cut points exploiting 173 
relevant data where possible although this has sometimes been at the expense of 174 
consistency in how the cut points have been chosen. The primary aim is to encourage 175 
uptake using a standardised approach  to identify sarcopenia in clinical practice, in much 176 
the same way cardiovascular risk factors have been introduced (table 3).15 177 
  178 
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Table 3. Reference values used to diagnose sarcopenia 179 
 180 
Measure Men Women 
Grip strength <27 kg <16 kg 
Appendicular Skeletal 
Muscle Mass (ASM)/height2 
<7 kg/m2 <5.5 kg/m2 
Gait speed ≤ 0·8 m/sec 
Timed Up and Go test ≥ 20 sec 
Based on those recommended by the EWGSOP2 15 181 
 182 
Muscle quality is a term that is now used widely. However, it may refer to two different 183 
concepts: the relation between strength and mass, and observable characteristics of 184 
muscle such as inter- or intramuscular adiposity. It may well prove to be a more relevant 185 
concept to health than muscle mass but as yet is not sufficiently defined for use in clinical 186 
practice.50 187 
 188 
Physical performance is defined as the ability to carry out physical tasks in order to 189 
function independently in daily life. It involves function of the whole body as opposed to 190 
function of a single organ and depends not only on skeletal muscle but on an intact 191 
musculoskeletal system integrated with the central and peripheral nervous systems and 192 
involvement of a range of other body systems.  It can be characterised using subjective or 193 
objective assessment of mobility, strength and balance, and commonly used single 194 
objective measures include gait speed and the 400 m timed walk. More complex 195 
composite measures such as the Short Physical Performance Battery (SPPB) and the Timed 196 
Up and Go (TUG) test) are also employed.51,52 In recent years there has been discussion 197 
about whether physical performance should be part of the definition of sarcopenia 3,5 or 198 
be used as an outcome measure.7 The latest EWGSOP2 definition suggests that physical 199 
performance should be considered a measure of the severity of sarcopenia.15 Grading the 200 
severity of sarcopenia is important both to predict outcomes and to choose the intensity 201 
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of interventions. Emerging evidence for this comes from some recent clinical trials that 202 
have shown that interventions may have different effects in severe sarcopenia. For 203 
example it appears that a more intensive, multi-dimensional intervention that always 204 
includes exercise is needed for severe sarcopenia. 53,54  205 
 206 
Blood biomarkers of sarcopenia are not yet available in clinical practice. Research in this 207 
area has proved complex for a number of reasons, including only recent progress towards 208 
a consensus definition of sarcopenia; increasing recognition of acute and chronic 209 
sarcopenia; the existence of many interacting pathways involved in the pathophysiology; 210 
and the impact of related conditions.55  211 
 212 
To date the most promising approach to measuring skeletal muscle mass is one based on 213 
the dilution of oral d3 creatine A. This is a non-invasive isotope dilution test that 214 
determines methyl-d3 creatine in fasting morning urine after an oral dose to calculate 215 
total skeletal mass. In a recent study, it was more strongly linked to outcomes such as 216 
physical performance and mobility in men than DXA lean mass.56–58 In contrast, DXA is 217 
useful for quantifying body fat, which can impact on muscle function and going forward it 218 
is likely that multiple approaches rather than individual measures will be needed for the 219 
required diagnostic accuracy.59–61 220 
 221 
Once sarcopenia has been confirmed, a systematic approach is recommended to ascertain 222 
the underlying causes.3 The most frequent causes of sarcopenia are described in Table 4. 223 
Sarcopenia can occur in association with a range of long-term conditions in mid-life hence 224 
the growing interest from a range of medical and surgical specialties. However most older 225 
patients will have more than one associated condition. When no evident cause of a 226 
gradual onset sarcopenia is present in an older person, age-associated (primary) 227 
sarcopenia is diagnosed. 228 
 229 
230 
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Table 4. Frequent underlying causes of sarcopenia 231 
 232 
Nutritional Low protein intake 
Low energy intake 
Micronutrient deficiency 
Malabsorption and other gastrointestinal conditions 
Anorexia (ageing, oral problems) 
Inactivity-related Bed rest / immobility / deconditioning 
Low activity / sedentary lifestyle 
Disease Bone and joint diseases 
Cardiorespiratory disorders including chronic heart failure 
and chronic obstructive pulmonary disease 
Metabolic disorders particularly diabetes mellitus 
Endocrine diseases particularly androgen deprivation 
Neurological disorders 
Cancer 
Liver and kidney disorders 
Iatrogenic Hospital admission 
Drug-related 
 233 
Differential diagnosis 234 
The three main conditions in the differential diagnosis of sarcopenia are malnutrition, 235 
cachexia and frailty.62–64 Malnutrition has been the focus of a recent global effort to reach 236 
a consensus definition and this is changing understanding of both malnutrition and 237 
sarcopenia. The Global Leadership Initiative on Malnutrition (GLIM) has included reduced 238 
muscle mass as one of the three phenotypic criteria of malnutrition.65 In parallel, the new 239 
EWGSOP2 definition of sarcopenia has put the focus on muscle function.15 Thus, a finding 240 
of reduced muscle mass with normal muscle strength would be more suggestive of 241 
malnutrition than sarcopenia whereas reduced muscle mass with impaired muscle 242 
function would lead to a diagnosis of sarcopenia. Hence there has been a move away from 243 
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the original approach of defining sarcopenia purely in terms of low muscle mass. Studies 244 
of sarcopenia in the context of other conditions such as cancer that only consider muscle 245 
mass may therefore be characterising malnutrition or cachexia rather than sarcopenia, as 246 
muscle function is usually not explored.66–68 247 
 248 
Cachexia is a term that has been used for decades to describe severe weight loss and 249 
muscle wasting associated with cancer, HIV and AIDS, or end-stage organ failure. Cachexia 250 
and sarcopenia may co-exist , and some aspects of the definition of sarcopenia, in 251 
particular low muscle mass, are included in modern definitions of cachexia.2,69 Cachexia 252 
has a complex pathophysiology including excess catabolism and inflammation, endocrine 253 
and neurological changes, that are different to those described in sarcopenia.70 The role of 254 
inflammation and cytokines seems to be more relevant in cachexia than in sarcopenia.71 255 
International consensus definitions of cachexia may guide clinical judgment.2,69 256 
 257 
Frailty has been defined as a state of vulnerability to poor resolution of homoeostasis 258 
after a stressor event as a consequence of cumulative decline in many physiological 259 
systems.72 Physical frailty is a subset of frailty characterised by the frailty phenotype 260 
involving unintentional weight loss, self-reported exhaustion, weakness (low grip 261 
strength), slow walking speed and low physical activity.73 Physical frailty and sarcopenia 262 
are therefore closely related and sarcopenia has been described as the ‘biological 263 
substrate of physical frailty’ as summarised in figure 3.74–79  264 
 265 
Disease burden 266 
 267 
The disease burden from sarcopenia arises because it is relatively common and associated 268 
with adverse effects on current as well as future health. Estimates of disease frequency 269 
are becoming more precise with evolution of the definition. A recent systematic review 270 
explored the effect of definition on the prevalence of sarcopenia in older community 271 
dwelling populations. This highlighted that the original 2010 EWGSOP definition resulted 272 
in one of the lowest pooled prevalence estimates (12·9%, 95% confidence interval: 9·9–273 
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15·5%) whereas the highest estimates (40·4%, 95% confidence interval: 19·5–61·2%) came 274 
from less current definitions that only used assessment of muscle mass.35 Muscle mass cut 275 
points have a stronger influence on prevalence estimates than muscle function cut 276 
points.80 Prevalence also depends on the setting, being more frequent in hospitalised 277 
patients, post-acute care settings, or in care homes than in the community.34,81  278 
 279 
Studies determining the incidence of sarcopenia are relatively sparse although there is 280 
emerging evidence that it rises with age.  There have been reports of an incidence of 1·6 % 281 
in European men and women aged 40-79 years using the EWGSOP definition;82 3·4% in a 282 
group of Chinese men and women mean age 72 years using the similar Asian Working 283 
Group definition;83 and 3·6% in English men and women aged 85 years using the EWGSOP 284 
definition.84  285 
 286 
The link between low muscle strength and adverse health outcomes is long established. A 287 
study dating back to the 1980s demonstrated a link between low grip strength before hip 288 
fracture surgery and poor postoperative outcomes.85 Two more recent linked systematic 289 
reviews have identified consistent relationships between low grip strength and increased 290 
mortality as well as some evidence for links between low grip strength and increased 291 
morbidity across the four domains of fracture, cognitive decline, cardiovascular disease 292 
and hospitalisation/ institutionalization.86,87 It has also been convincingly linked to frailty.88 293 
 294 
This literature now includes an increasing number of studies demonstrating the 295 
relationship between newer consensus definitions of sarcopenia and adverse health 296 
consequences including falls, functional decline, frailty, impaired quality of life, increased 297 
healthcare costs and mortality. A recent systematic review and meta-analysis showed 298 
consistent associations between EWGSOP defined sarcopenia and mortality with a pooled 299 
OR of 3·59 (95% CI 2·96–4·27) and a larger effect size in men and women aged 79 years 300 
and over.89 The review also showed that sarcopenia was associated with functional 301 
decline, a higher rate of falls and hospitalisation although the evidence for a link to 302 
fractures and length of stay was less consistent. Findings from a recent systematic review 303 
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confirm that quality of life across domains is impaired in sarcopenia whether measured 304 
using generic self-reported tools or disease-specific questionnaires.90 Unsurprisingly, in 305 
view of the link between sarcopenia and a range of adverse health outcomes, it has also 306 
been associated with increased healthcare costs,91 however the full extent of this has yet 307 
to be elucidated.92    308 
 309 
Pathophysiology 310 
Ageing disturbs the homeostasis of skeletal muscle which requires balance between 311 
hypertrophy and regeneration through complex and not yet fully understood mechanisms 312 
and pathways (figure 4). Ageing appears to result in an imbalance between muscle protein 313 
anabolic and catabolic pathways leading to overall loss of skeletal muscle. Cellular changes 314 
in sarcopenic muscle include a reduction in the size and number of myofibres, particularly 315 
affecting type II fibres. This is partly due to transition of muscle fibres from type II to type I 316 
with age, together with intra- and intermuscular fat infiltration (myosteatosis)  and a 317 
decreased number of type II fibre satellite cells.50,93–95 Recent findings suggest that 318 
pathogenic inter-relationships between adipose tissue and muscle are important in 319 
sarcopenia.26 Mitochondrial integrity in myocytes is also altered.96 Molecular changes in 320 
sarcopenic muscle involve alterations to the complex signaling pathway that includes 321 
insulin-like growth factor 1 (IGF-1), mTOR and FoxO transcription factors as well as other 322 
interlinked pathways.97 Neurologic signaling and control mechanisms also have an 323 
important role in muscle function.8,98 Deregulation in skeletal muscle gene expression, 324 
probably mediated through epigenetic changes and modulated via microRNAs, has also 325 
been described.99 326 
 327 
Recent research suggests that there is cross-talk between muscle and bone through  328 
endocrine factors such as myostatin, irisin, osteocalcin, and many others, although the 329 
relevance of this communication in the pathogenesis of sarcopenia has not been well 330 
established.100 There is also preliminary evidence for an association between the age-331 
related decline in production of apelin, an endogenous peptide induced by muscle 332 
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contraction, and decreased muscle function  through different pathways.101 A detailed 333 
review of the pathophysiology of sarcopenia is beyond the scope of this seminar but a 334 
number of  comprehensive reviews on this rapidly developing area are available.102,103  335 
 336 
Treatment: non-pharmacological approaches 337 
Understanding the pathophysiology of sarcopenia is key to developing effective new 338 
interventions and translational research in this area is growing rapidly. Recently, evidence-339 
based clinical practice guidelines have been published that provide strong 340 
recommendations for physical activity as the cornerstone for treatment of sarcopenia.33 341 
There is compelling evidence for the benefits of resistance exercise in improving skeletal 342 
muscle strength 104 and mass 105 individually, and growing evidence for its benefit in 343 
sarcopenia defined as a combination of both strength and mass. Two recent systematic 344 
reviews of exercise interventions in older adults with sarcopenia showed evidence of 345 
significantly improved strength, mass and balance although the number of trials 346 
specifically recruiting participants with sarcopenia was small, and the training effect 347 
inconsistent due to heterogeneity in the mode, duration and intensity of exercise 348 
employed.106,107 A more recent systematic review confirmed the effect of exercise in 349 
sarcopenic obesity.108 There is an important gap in the evidence needed to recommend a 350 
specific exercise programme for sarcopenia and wide variation in clinical practice is the 351 
current norm. 352 
 353 
The evidence on nutrition interventions is less consistent.33 A number of studies have 354 
investigated the effects of exercise combined with nutrition to treat sarcopenia and a 355 
systematic review of non-pharmacological interventions for well characterised sarcopenia 356 
and physical frailty in older patients confirmed the effectiveness of exercise with or 357 
without nutritional supplementation to improve physical performance although the 358 
overall quality of the evidence was low.107 Other reviews report variable findings although 359 
did not only include participants with sarcopenia.109,110 Large scale trials are now 360 
underway to specifically address this area such as the European SPRINTT trial.111,112 361 
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 362 
The place of nutritional interventions without exercise for the treatment of sarcopenia is 363 
much less clear although overall there appears to be evidence for ‘healthier’ dietary 364 
patterns that are adequate in quality in terms of intakes of protein, vitamin D, antioxidant 365 
nutrients and long-chain polyunsaturated fatty acids.113 However, many of the studies are 366 
observational in nature and high quality trials are less common. There remains debate 367 
about what constitutes an adequate intake of key nutrients such as protein as well as how 368 
they should be taken in terms of timing and distribution throughout the day.114 Although 369 
most recent consensus documents recommend increasing  protein intake in older 370 
people,115,116 the only intervention trial comparing normal versus increased protein intake 371 
in mobility impaired (albeit not sarcopenic) participants was negative.117 372 
 373 
High protein oral nutritional supplements may be more effective on some outcomes in the 374 
more specific context of sarcopenia with malnutrition.54,118  There is also considerable 375 
interest in the value of individual nutrients such as the essential amino acid leucine and its 376 
metabolite beta-hydroxy beta-methylbutyric acid (HMB) which have shown some effects 377 
in improving muscle mass and function,119,120 as has fish oil-derived n-3 (omega-3) 378 
polyunsaturated fatty acid (PUFA) therapy which increased muscle mass and function in 379 
one study of healthy older adults.121 380 
 381 
Treatment: pharmacological approaches 382 
At this time, there are no drugs approved for sarcopenia. A recent umbrella review has 383 
brought together systematic reviews and meta-analyses focusing on pharmacological 384 
interventions to improve muscle mass, strength and physical performance in older 385 
people.122 Interestingly very few studies identified baseline sarcopenia status, so the 386 
findings could only be generalised to older people rather than to people with sarcopenia. 387 
The umbrella review identified seven systematic reviews or meta-analyses involving ten 388 
pharmacological interventions: vitamin D, combined oestrogen-progesterone, 389 
dehydroepiandrosterone (DHEA), growth hormone, growth hormone-releasing hormone, 390 
 17 
combined testosterone-growth hormone, insulin-like growth factor-1, pioglitazone, 391 
testosterone, and angiotensin-converting enzyme inhibitors. There appeared to be a 392 
beneficial effect of vitamin D on strength and physical performance in women with low 393 
baseline levels (<25 nmol/l). An effect of testosterone on muscle mass more than strength 394 
or function, in men with low serum levels (<200–300 ng/dl), was also reported although 395 
findings from the high profile Testosterone Trials suggest limited benefit of testosterone 396 
for physical function, particularly in those with a slow walking speed, and caution 397 
regarding the cardiovascular side effect profile.123  398 
 399 
There is major research activity focused on developing new drugs for sarcopenia although 400 
progress has not been straightforward. Initial interest in selective androgen receptor 401 
modulators (SARMs) from mainly small phase I and II trials 124,125 has not been followed by 402 
convincing results from larger studies.  There is early evidence that myostatin inhibition 403 
may prove beneficial, consistent with recognition that myostatin acts as a brake on muscle 404 
differentiation, hypertrophy and protein synthesis. Results to date have not always been 405 
consistent but positive findings include those from a  phase II proof of concept trial that 406 
reported that a myostatin antibody was associated with increased muscle mass and 407 
improvement in some measures of physical performance in older, weak patients with a 408 
history of falling (but not diagnosed sarcopenia). 126 Another phase II randomised 409 
controlled proof of concept study of bimagrumab for sarcopenia found an increase in 410 
thigh muscle volume and increased gait speed in those slow at baseline.127 411 
 412 
Assessing the effect of interventions in research and clinical practice 413 
Assessment of the effect of interventions in research and clinical practice is required to 414 
enable them to be targeted appropriately. Unfortunately, there is still no clear consensus 415 
on what intermediate measures should be used either in research settings 128 or in clinical 416 
guidelines.33 In the absence of an established regulatory pathway for the development of 417 
interventions to date, the European Medicines Agency is using the SPRINTT trial to identify  418 
standard outcome measures that may be used in future drug research.111 419 
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 420 
At present, there is a case for using the same muscle strength and physical performance 421 
measures as utilised at the initial assessment. Improvements in the short physical 422 
performance battery (SPPB) of 1 point or gait speed over 0.1 m/s are recognised as of 423 
clinical relevance.129 In contrast minimum significant change has not been well defined for 424 
grip strength. Improvement in activities of daily living or in the number of falls may be 425 
even more relevant but not so straightforward to determine. However, there is increasing 426 
interest in developing Patient Reported Outcome Measures (PROMs) for sarcopenia.130 427 
Additionally, the SarQoL questionnaire, a sarcopenia-specific quality of life measure, can 428 
be used to understand the impact of the intervention on the global status of the 429 
patient.131 430 
 431 
Looking ahead 432 
The prevention of sarcopenia is a major area of research activity and observational 433 
epidemiological studies have identified important risk factors such as older age and low 434 
socioeconomic status as well as modifiable influences including low physical activity and 435 
poor diet,132 although the direct effects of alcohol consumption and  cigarette smoking are 436 
less clear.133 The focus of preventive strategies to date has been to modify these risk 437 
factors in later life, particularly to increase levels of physical activity,134,135 but more 438 
recently there has been consideration of the role of influences operating much earlier in 439 
the life course.  440 
 441 
Birth cohort studies have proved invaluable in this area and findings from the 442 
Hertfordshire Ageing Study 136 and Hertfordshire Cohort Study 137 provided the first 443 
evidence that small size at birth was linked with lower grip strength 60 or 70 years later, 444 
with confirmation in a subsequent systematic review.138 These findings have been 445 
explained by a life course approach to sarcopenia where it is proposed that muscle mass 446 
and function in older people depend not only on the rate of decline in later life and the 447 
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influences operating then, but also on the peak reached in young adulthood which is in 448 
turn determined by factors operating earlier in life.139  449 
 450 
Normative data for grip strength across the life course from UK studies (figure 5) 18 and 451 
from global grip strength data 140 are now available. They not only confirm the concept 452 
underlying a life course approach to sarcopenia - that skeletal muscle strength rises to a 453 
peak in early adulthood, then plateaus, before starting to decline - but have also provided 454 
a data driven approach to deriving cut points for low grip strength. For example, it has 455 
been proposed that a grip strength of 2·5 standard deviations or more below the young 456 
normal mean indicates low grip strength. This approach is analogous to that used to 457 
define osteoporosis in terms of low bone mineral density relative to a young normal 458 
mean. 459 
 460 
The importance of mid-life influences is also becoming increasingly apparent. For 461 
example, a study using data from the British National Survey of Health and Development 462 
(the 1946 birth cohort) has shown evidence of cumulative benefits of increased life time 463 
physical activity (LTPA) across mid-life on grip strength at the age of 60–64 years in men 464 
and women. This demonstrated that those in the upper third of LTPA score had a mean 465 
grip strength 2·11 kg (95% CI: 0·88-3·35) greater than those in the lower third after 466 
adjustment.141 467 
 468 
The life course approach to prevention is an important area going forward because it 469 
extends the opportunity for intervention from late old age to young old age, mid-life and 470 
before, when lifestyle changes such as regular physical activity and optimising diet may be 471 
easier to put into place.142 This also has the potential to enable public health messages to 472 
younger people encouraging  lifestyle modification such as increasing levels of physical 473 
activity, to refer not only to immediate but also to lifelong benefits for skeletal muscle 474 
health. However the evidence to date supporting this approach is largely observational 475 
and trials of life course interventions are needed using efficient methodologies such as 476 
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trials within birth cohorts.143 Linking a life course approach to understanding the 477 
underlying cellular and molecular mechanisms of sarcopenia has the potential to become 478 
a particularly powerful way to develop targeted treatment and preventive strategies.144  479 
 480 
Conclusions 481 
Sarcopenia is a progressive and generalised skeletal muscle disorder involving the 482 
accelerated loss of muscle mass and function that is associated with adverse health 483 
outcomes.  It is increasingly recognised not only as an age-related problem, but one 484 
associated with a range of long-term conditions. Several recent new consensus definitions 485 
have advanced the field in the last decade. Experimental medicine is focusing on 486 
translating understanding of pathophysiology into advances in the diagnosis, treatment 487 
and prevention of sarcopenia and a life course approach may provide a useful framework. 488 
Important research areas to be addressed include increasing understanding of underlying 489 
cellular and molecular mechanisms, the development of biomarkers, improved accuracy 490 
of diagnostic tests, and the design of effective strategies for sarcopenia across the life 491 
course.  492 
Search strategy and selection criteria  493 
We developed a structured search strategy in Pubmed for publications in English using the 494 
search term “sarcopenia” in combination with one of the following keywords: “definition”, 495 
“screening”, “diagnosis”, “muscle mass”, “strength”, “frailty”, “malnutrition”, “cachexia”, 496 
“outcomes”, “disability”, “mortality”, “pathophysiology”, “life course”, “treatment”, and 497 
“exercise”. We focused on clinical trials, meta-analysis and review articles. Only articles 498 
published after 2010 (when most definitions of sarcopenia were published) were 499 
searched, but we did not exclude major contributions published before. We referenced 500 
articles judged to be relevant to this Seminar. When many similar articles were available, 501 
the most recent were used. Additional papers were identified from personal libraries and 502 
the reference lists of retrieved articles. Review articles are used to provide useful details 503 
and references on specific areas that cannot be covered in depth in this Seminar.   504 
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Figures: 524 
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Figure 1. Percent loss of muscle mass and muscle strength with age in men. 526 
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Figure 2. A simple algorithm to diagnose sarcopenia in clinical practice 531 
 532 
Adapted from EWGSOP2.15 533 
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Figure 3. Relationship between sarcopenia, physical frailty and general frailty 535 
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Figure 4. The multifactorial aetiology of sarcopenia 538 
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Figure 5. UK Normative data for grip strength across the life course 545 
 546 
 547 
 548 
Centiles shown are 10th, 25th, 50th, 75th and 90th. Cut-points based on T-score of ≤ -2.5 549 
are shown for males and females (≤ 27 and 16kg, respectively). 550 
 551 
ADNFS Allied Dunbar National Fitness Survey, ALSPAC Avon Longitudinal Study of Parents 552 
and Children, ELSA English Longitudinal Study of Ageing, HAS Hertfordshire Ageing Study, 553 
HCS Hertfordshire Cohort Study,  LBC1921 and LBC1936 Lothian Birth Cohorts of 1921 and 554 
1936, N85 Newcastle 85+ Study, NSHD Medical Research Council National Survey of 555 
Health and Development, SWS Southampton Women’s Survey, SWSmp mothers and their 556 
partners from the SWS, T-07 West of Scotland Twenty-07 Study, UKHLS Understanding 557 
Society: the UK Household Panel Study. 558 
 559 
Adapted from Dodds R et al.11  560 
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